Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

"Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate" was originally created and published by ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

These ASX All Ords shares have soared 16% to 37% already in 2025. The post 3 ASX All Ords shares leading the charge in 2025 ...

Navi Mumbai: In a medical breakthrough at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, a 39-year-old Rijesh Nair, a ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

Researchers sought to determine whether patients with PMBCL may be able to forgo irradiation therapy during consolidation.